Thymosin-α1 for Recurrent Implantation Failure

Sex: Female

Ages: 18 Years – 40 Years

Healthy volunteers: No

Phase: PHASE2, PHASE3

Enrollment: 136

Sponsor: Fakih IVF Fertility Center

Summary

Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.

Eligibility Criteria

Inclusion Criteria: 1. -Women 18-40 years 2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos 3. \- Normal parental karyotypes 4. \- Normal uterine cavity on imaging 5. \- Negative antiphospholipid panel 6. \- Thyroid and prolactin controlled within local reference standards Exclusion Criteria: 1. Identified/correctable non-immune cause of RPL (chromosomal, anatomic, endocrine) 2. \- Active malignancy 3. -Active infection 4. \- Uncontrolled systemic disease 5. \- Current systemic immunosuppression

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07675980). StuddyBuddy aggregates publicly available trial information.